RNA Interference Screening Identifies Lenalidomide Sensitizers in Multiple Myeloma, Including RSK2

Blood - United States
doi 10.1182/blood-2014-05-577130
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Hematology

Related search

Lenalidomide Induced Stroke in Multiple Myeloma

Clinical Practice
MedicinePharmacology
2016English

Proteasome Inhibitors Block Ikaros Degradation by Lenalidomide in Multiple Myeloma

Haematologica
Hematology
2015English

Update on the Role of Lenalidomide in Patients With Multiple Myeloma

Therapeutic Advances in Hematology
Hematology
2018English

GRP-024 Antithrombotic Prophylaxis in Patients With Multiple Myeloma Being Treated With Lenalidomide

European Journal of Hospital Pharmacy: Science and Practice
Pharmacy
2013English

An RNA Interference Screen Identifies New Avenues for Nephroprotection

Cell Death and Differentiation
Cell BiologyMolecular Biology
2015English

Optimizing the Use of Lenalidomide in Relapsed or Refractory Multiple Myeloma: Consensus Statement

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

Exome Sequencing Identifies Germline Variants in DIS3 in Familial Multiple Myeloma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2019English

Screening of JAK2 V617F Mutation in Multiple Myeloma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2006English

Disseminated Cryptococcosis in a Patient With Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone

Internal Medicine
Internal MedicineMedicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy